Tong Ren Tang healthcare unit pulls Hong Kong IPO scheduled for Monday
A view of Exchange Square in Central, where Hong Kong’s bourse operator has its headquarters, on March 13, 2026.
Photo: Jelly Tse Beijing Tong Ren Tang Healthcare Investment, a provider of healthcare services based on traditional Chinese medicine, postponed its Hong Kong initial public offering (IPO) on Friday, citing “prevailing market conditions” and other factors.
The company was one of six trading debuts slated for Monday, including an exchange-traded fund (ETF) and firms involved in AI and robotics.
The firm had aimed to raise up to HK$897.7 million (US$115 million) by offering 108.15 million shares at between HK$7.30 and HK$8.30 each.
Retail and institutional investors who submitted applications for the company’s shares would receive full refunds by March 30, according to a filing with the Hong Kong stock exchange.
Investor demand had been tepid, with the public tranche 4.85 times oversubscribed, according to data compiled by broker Futu.
About 10 per cent of the offering was earmarked for retail investors, with the remainder allocated to institutional investors. “Its public tranche drew relatively lukewarm demand compared with other IPOs in the market,” said Mike Leung Kit-man, director of Wocom Securities. “The management likely weighed the weak subscription, recent market volatility and the risk of a poor post-listing performance before deciding to pull the deal.” The company cleared its listing hearing in the latter part of last year but waited months before launching the offer.
It only moved ahead recently as the financial data in its application neared expiry, Leung added.
Founded in 2015, the company is a healthcare services arm of the Tong Ren Tang Group, one of China’s oldest traditional Chinese medicine brands, which traces its roots to 1669.
In 2024, Beijing Tong Ren Tang Healthcare Investment was China’s largest private-sector hospital network focused on traditional Chinese medicine, commanding a 1.7 per cent market share, according to its prospectus.
The postponed offering would have made the company the group’s fourth listed entity, following Beijing Tongrentang, Tong Ren Tang Technologies, and Tong Ren Tang Chinese Medicine.
The other debuts on the agenda on Monday are industrial automation and robotics specialist Guangdong Huayan Robotics, AI-powered diagnostics platform Hangzhou Diagens Biotechnology, AI and machine-vision solutions provider Shandong Extreme Vision Technology, semiconductor maker Epiworld International and
原文链接: 南华早报